Oral and oropharyngeal cancer: epidemiology and survival analysis

Moro, Juliana da Silva; Maroneze, Marília Cunha; Ardenghi, Thiago Machado; Barin, Luisa Machado; Danesi, Cristiane Cademartori

doi:10.1590/s1679-45082018ao4248

Cited by 87 publications

(103 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In 11 hospitals in Europe, 45% of the OC patients had stage III-IV SCC (15). (14). Thus, the OS rate for patients with OC has been around 55% at most treatment centers.…”

Section: ' Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Survival trends of patients with oral and oropharyngeal cancer treated at a cancer center in São Paulo, Brazil

Kowalski¹,

Oliveira²,

López³

et al. 2020

Clinics

View full text Add to dashboard Cite

OBJECTIVE:We aimed to estimate the overall survival (OS) and conditional survival (CS) in patients diagnosed with oral and oropharyngeal squamous cell carcinoma (SCC) and to determine their survival trends. METHODS:The study included all consecutive patients treated at the A.C. Camargo Cancer Center for oral or oropharyngeal SCC between 2001 and 2012. Data were obtained from the Hospital Cancer Registry. OS and CS were analyzed using the Kaplan-Meier method to evaluate the probability of survival with Cox predictor models. RESULTS: Data of 505 oral and 380 oropharyngeal SCC patients obtained in 2001-2006 and 2007-2012 were analyzed. Most of the oral SCC (59%) and oropharyngeal SCC (90%) patients had stages III-IV SCC. The 5-year OS for patients with oral SCC was 51.7%, with no significant difference between the first and second periods. The CS rates in 2007-2012 were 65% after the first year and 86% up to the fifth year. For oropharyngeal SCC, the 5-year OS rate was 45.0% in the first period. The survival rate increased to 49.1% from 2007 to 2012, with a reduction in the risk of death (HR=0.69;0.52-09.2). The CS estimates from 2007 to 2012 were 59% after the first year and 75% up to the fifth year. CONCLUSION: Survival across the two time periods remained stable for oral SCC but showed a significant increase for oropharyngeal SCC, possibly because of improvements in the patients' response to radiotherapy, such as intensity-modulated radiation therapy, and the use of more accurate diagnostic imaging approaches.

show abstract

“…In 11 hospitals in Europe, 45% of the OC patients had stage III-IV SCC (15). (14). Thus, the OS rate for patients with OC has been around 55% at most treatment centers.…”

Section: ' Discussionmentioning

confidence: 99%

“…In Maceio, northeast of Brazil, the 5-year OS for oropharyngeal cancer was 27.8% (12,13). In Santa Maria, south of Brazil, the 5-year OS for OC and oropharyngeal cancer was 42%; however, patients with oropharyngeal cancer had the worst survival rates (14).…”

Section: ' Introductionmentioning

confidence: 98%

Survival trends of patients with oral and oropharyngeal cancer treated at a cancer center in São Paulo, Brazil

Kowalski¹,

Oliveira²,

López³

et al. 2020

Clinics

View full text Add to dashboard Cite

show abstract

“…Na maioria dos casos, as ocupações consideradas de alto risco diminuíram seus índices e as ocupações de baixo risco aumentaram seus índices, após o ajuste para o uso de tabaco e álcool, conforme o esperado 13 . Em relação aos fatores de risco, nos homens acima de 50 anos, houve um aumento significativo de CCO relacionado ao HPV; enquanto, para as mulheres, a incidência permaneceu estável 14 ressalta Moro et al 15 . Importante salientar que, nas próximas décadas, o fator de risco em pacientes mais velhos com maior exponencial de crescimento associado ao CCO será o HPV 16 .…”

Section: Discussionunclassified

Conhecimento de Universitários da Área da Saúde sobre o Câncer de Cavidade Oral

Ganzer¹,

Wagner²

2019

Rev. Bras. Cancerol.

View full text Add to dashboard Cite

Introdução: O câncer de cabeça e pescoço engloba um grupo heterogêneo de neoplasias malignas originadas na cavidade oral, faringe, laringe, seios paranasais, cavidade nasal, glândulas salivares e tireoide. Objetivo: Este estudo buscou avaliar o conhecimento dos universitários da área da saúde sobre o câncer de cavidade oral. Método: Estudo do tipo epidemiológico, transversal, descritivo, quali-quantitativo com amostra não probabilística de conveniência. Os universitários receberam, via formulário on-line, um questionário com 24 questões aplicadas que abordavam os fatores de risco, sintomatologia, aspectos clínicos, autoexame, prevenção e tratamento. Resultados: Participaram do estudo 110 universitários da área da saúde (58 = primeiro ano e 52 = último ano), distribuídos nos cursos de fisioterapia, odontologia, psicologia, educação física, enfermagem, medicina e nutrição. Em relação à média de acertos dos questionários, os universitários do primeiro ano obtiveram 77,65% (±21,09) de acertos, e os universitários do último ano, 82,37% (±19,88). As questões que obtiveram menores taxas de acertos foram as relacionadas à incidência do câncer de boca no Brasil; 43 (39%) acertaram e 52 (47,3%) dos universitários desconhecem a idade em que maioria dos casos são diagnosticados. Conclusão: Apesar de o câncer de cavidade oral ser crescente, formas de prevenção e diagnóstico precoce reservam maiores chances de cura. A partir deste estudo, pôde-se concluir que os universitários dos cursos da área da saúde, principalmente do último ano, parecem estar aptos a informar à população a respeito do câncer de cavidade oral.

show abstract

“…Head and neck cancers pose a serious public health problem due to its high incidence, prevalence, and mortality (1)(2)(3). Among these, cancers affecting the oral cavity rank in the top 20 of all malignant tumors worldwide, with more than 350,000 new cases reported in 2018 (4).…”

Section: Introductionmentioning

confidence: 99%

Inhibition of CAL27 Oral Squamous Carcinoma Cell by Targeting Hedgehog Pathway With Vismodegib or Itraconazole

et al. 2020

View full text Add to dashboard Cite

Oral Squamous Cell Carcinoma (OSCC) presents an important challenge for the health systems worldwide. Thus, unraveling the biological mechanisms involved in OSCC pathogenesis is essential to the discovery of new drugs with anticancer potential. The Hedgehog (HH) pathway has shown promising results as a therapeutic target both in vitro and in vivo. This study aimed to investigate the effects of vismodegib and itraconazole on the expression of Hedgehog (HH) genes (PTCH1, SMO, and GLI1), cell cycle and cell death in OSCC cells. Alamar Blue assay was used to assess the cytotoxicity of vismodegib and itraconazole in a panel of oral cancer cell lines, including CAL27. The expression of HH signaling components after treatment with vismodegib and itraconazole, at concentrations of 25 or 50 μg/ml was evaluated by qPCR. Cell cycle and apoptosis were evaluated by flow cytometry after 72 h treatment with 50 μg/ml of vismodegib or itraconazole. HH signaling was activated in OSCC cell lines CAL27, SCC4, SCC9, and HSC3. Vismodegib and itraconazole significantly reduced CAL27 cell viability after 48 h of treatment. Gene expression of PTCH1, SMO, and GLI1 decreased in response to 24 h of treatment with vismodegib or itraconazole. Furthermore, CAL27 cells exhibited alterations in morphology, cell size, and cellular granularity. An increase in the DNA fragmentation was observed after treatment and both inhibitors induced apoptosis after 72 h. In conclusion, SMO inhibitors vismodegib and itraconazole demonstrably reduced the expression of HH genes in CAL27 OSCC cell line. In addition, treatment with vismodegib and itraconazole reduced cellular viability and altered the morphology of CAL27 cells, and also induced apoptosis.

show abstract

Oral and oropharyngeal cancer: epidemiology and survival analysis

Cited by 87 publications

References 21 publications

Survival trends of patients with oral and oropharyngeal cancer treated at a cancer center in São Paulo, Brazil

Survival trends of patients with oral and oropharyngeal cancer treated at a cancer center in São Paulo, Brazil

Conhecimento de Universitários da Área da Saúde sobre o Câncer de Cavidade Oral

Inhibition of CAL27 Oral Squamous Carcinoma Cell by Targeting Hedgehog Pathway With Vismodegib or Itraconazole

Contact Info

Product

Resources

About